scholarly journals Clinical parameters of inflammatory bowel disease in children do not correlate with four common polymorphisms of the transforming growth factor β1 gene.

2011 ◽  
Vol 58 (4) ◽  
Author(s):  
Anna Liberek ◽  
Joanna Jakóbkiewicz-Banecka ◽  
Anna Kloska ◽  
Joanna Świderska ◽  
Zbigniew Kmieć ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Growth Factor ◽  
Intestinal Mucosa ◽  
Bowel Disease ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β1 ◽  
Control Group ◽  
Clinical Parameters ◽  
Inflammatory Bowel ◽  
Tgf Β1

Transforming growth factor β1 (TGF-β1) is a cytokine affecting cell proliferation and development, which also has an immunomodulatory activity. Correlations between polymorphisms of the TGF-β1 gene and clinical parameters of inflammatory bowel disease (IBD) were reported previously in adults. Here, we tested whether such correlations occur in pediatric patients suffering from IBD. One hundred and four pediatric IBD patients were involved in this study. Among them, 36 were diagnosed with Crohn's Disease (CD) and 68 were diagnosed with ulcerative colitis (UC). The control group consisted of 103 children, in which IBD was excluded. TGF-β1 levels were determined in plasma and intestinal mucosa samples. The presence of the TGF β1 protein and the amount of TGF β1 mRNA were estimated in intestinal mucosa by immunohistochemistry and reverse transcription Real-Time PCR, respectively. Four common polymorphisms of the TGF-β1 gene were investigated: -800G/A, -509C/T, 869T/C and 915G/C. No significant correlation between TGF-β1 genotypes and (i) TGF-β1 levels in plasma and tissue samples, (ii) TGF-β1 gene expression efficiency in intestinal mucosa, (iii) IBD clinical parameters and (iv) inflammatory activity could be detected in children suffering from IBD. We conclude that, contrary to previous suggestions, the four common polymorphisms of the TGF-β1 gene do not influence the susceptibility to or clinical parameters of IBD in the tested population of children.

scholarly journals Transforming growth factor β1 protein and mRNA levels in inflammatory bowel diseases: towards solving the contradictions by longitudinal assessment of the protein and mRNA amounts.

1970 ◽  
Vol 60 (4) ◽  
Author(s):  
Anna Liberek ◽  
Zbigniew Kmieć ◽  
Piotr M Wierzbicki ◽  
Joanna Jakóbkiewicz-Banecka ◽  
Tomasz Liberek ◽  
...  
Keyword(s):  
Growth Factor ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β1 ◽  
Mrna Levels ◽  
Longitudinal Assessment ◽  
Active Stage ◽  
Intestinal Tissue ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Tgf Β1

Previously published studies on levels of the transforming growth factor-β1 (TGF-β1) protein and mRNA of the corresponding gene in patients suffering from inflammatory bowel diseases (IBD) gave varying results, leading to contradictory conclusions. To solve the contradictions, we aimed to assess longitudinally TGF-β1 protein and mRNA levels at different stages of the disease in children suffering from IBD. The study group consisted of 19 pediatric patients with IBD at the age between 3.5 and 18.4 years. The control group consisted of 42 children aged between 2.0 and 18.0 years. The plasma TGF-β1 concentration was measured with ELISA. mRNA levels of the TGF-β1 gene isolated from samples of the intestinal tissue were assessed by reverse transcription and real-time PCR. Levels of TGF-β1 protein in plasma and corresponding mRNA in intestinal tissue were significantly higher in IBD patients than in controls. TGF-β1 and corresponding transcripts were also more abundant in plasma and intestinal tissue, respectively, in patients at the active stage of the disease than during remission. In every single IBD patient, plasma TGF-β1 level and mRNA level in intestinal tissue was higher at the active stage of the disease than during remission. Levels of TGF-β1 and corresponding mRNA are elevated during the active stage of IBD but not during the remission. Longitudinal assessment of this cytokine in a single patient may help to monitor the clinical course of IBD.

scholarly journals Study Of Coleus Amboinicus Extract in Increasing of Transforming Growth Factor-β1 (TGF-β1) Concentration and Docking Prediction Quercetin Derivatives in 4X0M Receptor on Uric Acid-Induced in Rats

2020 ◽  
Vol 17 ◽  
Author(s):  
Rondius Solfaine ◽  
Lailatul Muniroh ◽  
Iwan Sahrial Hamid
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Uric Acid ◽  
Growth Factor ◽  
Serum Creatinine ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β1 ◽  
Control Group ◽  
Tgf Β1 ◽  
Coleus Amboinicus

Background: Coleus amboinicus extracts are known to have anti-oxidant activity, anti-platelet aggregations, antibacterial, anticancer and anti-inflammation. Objective: To evaluate Coleus amboinicus (CA) extracts in increasing of transforming growth factor-β1 concentration and molecular docking prediction of quercetin on receptor 4X0M (TGF-β1), measuring the levels of BUN, serum creatinine and Glutathione Peroxidase (GPx) on uric acid-induced rats. Method: Fourty-two male Wistar rats (Rattus norvegicus), 3 months, 150-200 g were allocated into 3 groups (n=14). The control group received placebo (U-0), treatment group were administered orally with uric acid 1,5% and oxonic acid 2% (U1) and received 500 mg/kg bw of the CA extracts (U-2) respectively for 30 days. Blood serums collected for analysis of creatinine and BUN concentrations. All groups were sacrificed to collect kidney for measuring of GPx activity and TGF-β1 concentration was conducted by avidin-horseradish peroxidase (HRP) sandwich-Elisa. Kidney organ was collected to histopathological analyzed by HE and PAS staining. Results: CA extract analyzed by TLC has a relative fraction of flavonoids, terpenes, saponins, polyphenols and alkaloids. Induction with uric acid has proven to causes acute renal failure with indicated of elevated BUN, serum creatinine concentration and necrotic lesions of tubular membrane in treatment groups. Treatment of CA extract at a dose of 500 mg/kg bw could increase of GPx and of TGF-β1 concentration significantly (p≤0.05). Quercetin as a marker compound of CA extract has stronger bind to the TGF-β1receptor (PDB code: 4X0M) than its of 3WA_601 ligand by in silico. Conclusion: CA extract is proven to inhibit acute renal failure by increasing of TGF-β1concentration and has strong binding of its receptor.

The opposing roles of IL-21 and TGFβ1 in chronic inflammatory bowel disease

2011 ◽  
Vol 39 (4) ◽  
pp. 1061-1066 ◽  
Author(s):  
Thomas T. MacDonald ◽  
Iona Bell ◽  
Giovanni Monteleone
Keyword(s):  
Inflammatory Bowel Disease ◽  
T Cells ◽  
T Cell ◽  
Cell Survival ◽  
Bowel Disease ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β1 ◽  
Chronic Inflammatory Bowel Disease ◽  
Inflammatory Bowel ◽  
T Cell Survival

There are large numbers of T-cells in the mucosa of the intestine in healthy individuals. The stimulus for their presence is the normal gut microbiota. For unknown reasons, in patients with IBD (inflammatory bowel disease), there is inappropriate and chronic activation of mucosal T-cells which leads to gut damage and severe morbidity. In one form of IBD, namely Crohn's disease, the T-cells are probably responding to the microbiota. T-cell survival in the gut wall is dependent on pro-inflammatory cytokines and antibody-mediated inhibition of one of these cytokines, TNFα (tumour necrosis factor α), has shown efficacy in patients, thus encouraging investigations of other ways to control mucosal T-cell responses. In the present paper, we give a brief review of T-cell immunology in IBD and then discuss how two particular cytokines, namely IL-21 (interleukin 21), which is generally pro-inflammatory and important in gut T-cell survival and in maintaining Th17 cells, and TGFβ1 (transforming growth factor β1), which is generally immunosuppressive, play opposing roles in gut inflammation.

Cognitive Impairment, P300, and Transforming Growth Factor β1 in Different Forms of Dementia

2020 ◽  
Vol 78 (2) ◽  
pp. 837-845
Author(s):  
Eman M. Khedr ◽  
Asmaa M.S. Gomaa ◽  
Omyma G. Ahmed ◽  
Hanaa M.M. Sayed ◽  
Ayman Gamea
Keyword(s):  
Growth Factor ◽  
Transforming Growth Factor ◽  
Serum Levels ◽  
Transforming Growth Factor Β1 ◽  
Control Group ◽  
P300 Latency ◽  
Memory Assessment ◽  
Diagnostic And Statistical Manual ◽  
Dementia Patients ◽  
Tgf Β1

Background: There are currently few biomarkers to assist in early diagnosis of dementias. Objective: To distinguish between different dementias: Alzheimer’s disease (AD), vascular dementia (VaD), and Parkinson’s disease dementia (PDD) using simple neurophysiologic (P300) and laboratory markers (transforming growth factor β1 “TGF-β1”). Methods: The study included 15 patients for each type of dementia and 25 age- and sex-matched control subjects. Dementia patients were diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders 4th edition-revised (DSM-IV-R). Modified Mini-Mental State Examination (3MS), Memory Assessment Scale (MAS), P300, and TGF-β1 were examined for each participant. Results: There were no significant differences between groups as regard to age, sex, and education, social, and economic levels. Significant differences between groups were observed in registration and naming variables of the 3MS. Compared with the control group, P300 latency was prolonged in all groups, although to a greater extent in AD and PDD than in VaD. A serum level of TGF-β1 was significantly elevated in all groups but was significantly higher in AD and VaD than in PDD. 3MS tended to correlate with P300 more than TGF-β1, and to be stronger in AD than the other groups. Conclusion: Measurements of P300 latency and serum levels of TGF-β1 can help distinguish AD, PDD, and VaD. P300 was more prolonged in AD and PDD than VaD whereas TGF-β1 was significantly higher in AD and VaD than PDD. Thus P300 and TGF-β1 may be useful biomarkers for detection and evaluation of the extent of cognitive dysfunction.

scholarly journals Glutathione S-Transferase Omega-2 and Transforming Growth Factor-β1 Polymorphisms in Iranian Glaucoma Patients

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Shahram Bamdad ◽  
Fatemeh Sanie-Jahromi ◽  
Marzieh Alamolhoda ◽  
Nasrin Masihpour ◽  
Mohammad-Hossein Karimi
Keyword(s):  
Growth Factor ◽  
Transforming Growth Factor ◽  
Open Angle Glaucoma ◽  
Transforming Growth Factor Β1 ◽  
Angle Closure ◽  
Control Group ◽  
Glutathione S Transferase ◽  
Significant Difference ◽  
And Control ◽  
Tgf Β1

Background. To investigate the association of glutathione s-transferase omega 2 (GSTO2) (142N > D) and transforming growth factor-β1 (TGF-β1) (869T > C) gene polymorphisms on the pathogenesis of two common types of glaucoma (including primary open-angle glaucoma (POAG) and chronic angle-closure glaucoma (CACG)) in the Iranian population. Methods. A total of 100 glaucoma patients (60% males and 40% females with an age mean ± SD of 34.66 ± 14.25 years; 56 cases of POAG and 44 cases of CACG) were enrolled in this study. GSTO2 (142N > D) and TGF-β1 (869T > C) polymorphisms were evaluated by PCR-based methods in patients and controls. Results. At locus GSTO2 (142N > D), the odds of ND genotype with respect to DD and NN genotypes were 1.55 and 2.08 times higher in POAG and CACG patients compared to those of patients in the control group (95% CI1: 0.80–2.98; 95% CI2: 1.00–4.33) which was statistically significant in CACG patients. However, the odds of DD and NN genotypes against the reference genotype in two patients group were not statistically significant as compared to those of patients in the control group. There was a significant association between the ND genotype and male patients (OR = 2.28, 95% CI: 1.06–4.92). The analysis of TGF-β1 (869T > C) polymorphisms showed no significant difference between the genotypes of TGF-β1 (869T > C) polymorphisms in patients and control groups; however, the CT genotype of TGF-β1 significantly differed between female controls and patients (OR = 0.42, 95% CI: 0.18–0.96). Conclusion. The presented results revealed that there was a significant association between the ND genotype of GSTO2 and the pathogenesis of glaucoma. Furthermore, this genotype can be considered as a sex-dependent genetic risk factor for the development of glaucoma. In contrast, the CT genotype of TGF-β1 is suggested to be a protective genetic factor against the pathogenesis of glaucoma.

Sign in / Sign up

Export Citation Format

Share Document